Hephaitos Pharma is a preclinical stage biotech company that is at the forefront of developing the next generation of oncology treatments. Their mission is to boost the immune system in order to treat incurable cancers through immunotherapy. Currently, only 10% of patients can be cured using immunotherapy, so Hephaitos Pharma aims to take it to the next level of efficiency.

Their team consists of international experts and experienced professionals who bring their knowledge and expertise to the table. Led by Chairwoman and CSO Martine CAROFF, an EU Woman Innovators Prize winner, they have a dedicated team of individuals specializing in various fields such as biochemistry, research, immunology, and business development. Hephaitos Pharma's innovative platform, ONCO-Boost, is a first-in-class immunostimulant that stimulates the immune system's response to recruit and mature immune defenses.

By blocking recognition pathways between tumor cells and host cells, ONCO-Boost enables the treatment of tumors that were previously resistant to traditional methods. With their groundbreaking research and development, Hephaitos Pharma is on a path to revolutionize cancer therapy and provide hope to patients with incurable cancers